title: [Hepatitis C virus-related cryoglobulinemic vasculitis with renal involvement: current possibilities of treatment].
abstract: The paper considers the specific features of renal involvement developing in chronic infection caused by hepatitis C virus (HCV) and the current possibilities of treatment. It details the clinical and morphological manifestations of HCV-related cryoglobulinemic glomerulonephritis, and criteria for its diagnosis and prognosis. The author discuss new approaches to treating (severe cryoglobulinemic vasculitis with renal involvement in particular)--antiviral therapy (pegylated interferon-alpha/ribavirin) in combination with biological agents (anti-CD monoclonal antibodies, such as rituximab) to achieve clinical, virological, immunological remissions and a response at a molecular level--to eliminate oligo- and monoclonal B lymphocyte proliferation.
authors.forename: N B
authors.initials: NB
authors.lastname: Gordovskaia
authors.forename: L V
authors.initials: LV
authors.lastname: Kozlovskaia
authors.forename: S Iu
authors.initials: SIu
authors.lastname: Milovanova
authors.forename: T M
authors.initials: TM
authors.lastname: Ignatova
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Korotchaeva
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003449:Cryoglobulinemia / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D004359:Drug Therapy, Combination; D005921:Glomerulonephritis / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D006526:Hepatitis C / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D000069283:Rituximab; D014657:Vasculitis / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000069283:Rituximab; C100416:peginterferon alfa-2a